These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10514024)

  • 1. Postmarketing studies: the work of the Drug Safety Research Unit.
    Finney DJ
    Drug Saf; 1999 Oct; 21(4):337-8. PubMed ID: 10514024
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-marketing drug safety in the era of genomic medicine.
    Zavras AI
    J Dent Res; 2005 Feb; 84(2):105-6. PubMed ID: 15668326
    [No Abstract]   [Full Text] [Related]  

  • 3. Approval times and the safety of new pharmaceuticals.
    Rudholm N
    Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. After Avandia, some seek split in drug approval and monitoring.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of routine healthcare data in safe and cost-effective drug use.
    Currie CJ; MacDonald TM
    Drug Saf; 2000 Feb; 22(2):97-102. PubMed ID: 10672892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study Highlights the Need for Continuing Postapproval Drug Monitoring.
    Stockwell S
    Am J Nurs; 2017 Aug; 117(8):16. PubMed ID: 28749872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 8. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor monitoring and processes are responsible for errors in one in 20 GP prescriptions.
    Torjesen I
    BMJ; 2012 May; 344():e3163. PubMed ID: 22551718
    [No Abstract]   [Full Text] [Related]  

  • 11. What about the sheer number of drugs prescribed?
    van't Hoff H
    BMJ; 2012 May; 344():e3561. PubMed ID: 22619202
    [No Abstract]   [Full Text] [Related]  

  • 12. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
    Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler Postmarketing surveillance studies remain unethical.
    Patterson C
    BMJ; 1999 Mar; 318(7186):810-11. PubMed ID: 10215393
    [No Abstract]   [Full Text] [Related]  

  • 14. [Drug surveillance in patients of advanced-age].
    Bol Oficina Sanit Panam; 1984 Apr; 96(4):342-52. PubMed ID: 6233994
    [No Abstract]   [Full Text] [Related]  

  • 15. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens.
    Cramer JA
    Drugs; 1995 Mar; 49(3):321-7. PubMed ID: 7774509
    [No Abstract]   [Full Text] [Related]  

  • 16. Withdrawing drugs: nefazodone, the start of the latest saga.
    Edwards IR
    Lancet; 2003 Apr; 361(9365):1240. PubMed ID: 12699949
    [No Abstract]   [Full Text] [Related]  

  • 17. Postmarketing drug surveillance: what it would take to make it work.
    CMAJ; 2001 Nov; 165(10):1293, 1295. PubMed ID: 11760966
    [No Abstract]   [Full Text] [Related]  

  • 18. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating drugs after their approval for clinical use.
    Ray WA; Griffin MR; Avorn J
    N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract]   [Full Text] [Related]  

  • 20. Postmarketing surveillance for drug safety: surely we can do better.
    Griffin MR; Stein CM; Ray WA
    Clin Pharmacol Ther; 2004 Jun; 75(6):491-4. PubMed ID: 15179403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.